文献速递炎症性肠病

维得利珠单抗与TNFα拮抗剂在IBD患者中的严重感染风险比较

Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-02-25

基于行政索赔数据库的回顾性队列研究,纳入2014-2018年新使用TNFα拮抗剂或维得利珠单抗的IBD患者,比较严重感染风险。维得利珠单抗在溃疡性结肠炎患者中与严重感染风险降低46%相关(HR 0.54,95%CI 0.35-0.83),但在克罗恩病患者中无显著差异(HR 1.30,95%CI 0.80-2.11)。

要点

  • UC患者使用维得利珠单抗比TNFα拮抗剂严重感染风险更低(HR 0.54)。
  • CD患者两种药物严重感染风险无显著差异(HR 1.30,95%CI 0.80-2.11)。
  • 维得利珠单抗在UC中降低肠外严重感染,在CD中增加胃肠道严重感染。

核心结论

  • 在IBD患者中,维得利珠单抗相比TNFα拮抗剂与UC患者严重感染风险降低相关,但在CD患者中无显著差异。

研究设计与样本

  • 回顾性队列研究,使用行政索赔数据库,纳入2014-2018年新使用TNFα拮抗剂或维得利珠单抗且治疗前后至少1年有保险覆盖的IBD患者。
  • 采用边际结构Cox比例风险模型,调整基线疾病特征、医疗利用、合并症及时间变化的皮质类固醇、免疫调节剂和阿片类药物使用。
  • 共纳入4881例TNFα拮抗剂治疗患者(年龄41±15岁,60%为CD)和1106例维得利珠单抗治疗患者(年龄44±16岁,39%为CD)。

主要发现

  • TNFα拮抗剂组434例发生严重感染,随访5786人年;维得利珠单抗组86例发生严重感染,随访1040人年。
  • UC患者中,维得利珠单抗相比TNFα拮抗剂严重感染风险降低46%(HR 0.54,95%CI 0.35-0.83)。
  • CD患者中,两组严重感染风险无显著差异(HR 1.30,95%CI 0.80-2.11)。
  • UC患者中维得利珠单抗与肠外严重感染风险降低相关,CD患者中与胃肠道严重感染风险升高相关。

临床怎么用

  • 对于UC患者,选择维得利珠单抗可能降低严重感染风险,尤其需考虑感染风险时。
  • 对于CD患者,维得利珠单抗与TNFα拮抗剂的严重感染风险无显著差异,决策需综合其他因素。

局限性

  • 观察性研究设计可能存在残余混杂。
  • 使用行政索赔数据库,严重感染定义基于住院感染,可能受编码准确性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We conducted a retrospective cohort study comparing the risk of serious infections between patients treated with tumor necrosis factor-a (TNFa) antagonists vs. vedolizumab in patients with inflammatory bowel diseases (IBD). METHODS: Using an administrative claims database, we identified patients with IBD who were new-users of either TNFa antagonists or vedolizumab between 2014-2018 and had insurance coverage for at least 1y before and after treatment initiation. We compared the risk of serious infections (infections requiring hospitalization) between patients treated with vedolizumab or TNFa antagonists using marginal structural Cox proportional hazard models adjusted for baseline disease characteristics, healthcare utilization, comorbidities, and time-varying use of corticosteroids, immunomodulators and opiates. RESULTS: We included 4881 patients treated with TNFa antagonists (age, 41 ± 15y, 60% with Crohn's disease [CD]) of whom 434 developed serious infections over 5786 person-year [PY] follow-up, and 1106 patients treated with vedolizumab (age, 44 ± 16y, 39% with CD) of whom 86 developed serious infections over 1040-PY follow-up. Vedolizumab was associated with 46% lower risk of serious infections as compared with TNFa antagonists in patients with ulcerative colitis (HR,0.54 [95% CI,0.35-0.83), but no significant differences were observed in patients with CD (HR,1.30 [0.80-2.11]). Vedolizumab was associated with lower risk of extra-intestinal serious infections in patients with UC, but higher risk of gastrointestinal serious infections in patients with CD. CONCLUSIONS: In an observational study of patients with IBD, vedolizumab was associated with lower risk of serious infections as compared with TNFa antagonists, in patients with UC, but not in patients with CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singh S, Heien HC, Herrin J, et al. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021. PMID: 33640480. doi:10.1016/j.cgh.2021.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。